NovoCure's Cash from Financing Activities rose 10041700.0% to $100.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.8 million, marking a year-over-year increase of 2378.38%. This contributed to the annual value of $90.3 million for FY2024, which is 47208.46% up from last year.
As of Q3 2025, NovoCure's Cash from Financing Activities stood at $100.5 million, which was up 10041700.0% from $2.4 million recorded in Q2 2025.
In the past 5 years, NovoCure's Cash from Financing Activities registered a high of $100.5 million during Q3 2025, and its lowest value of $100000.0 during Q3 2024.
Moreover, its 5-year median value for Cash from Financing Activities was $3.7 million (2021), whereas its average is $13.4 million.
In the last 5 years, NovoCure's Cash from Financing Activities crashed by 9936.03% in 2021 and then soared by 10041700.0% in 2025.
Over the past 5 years, NovoCure's Cash from Financing Activities (Quarter) stood at $3.7 million in 2021, then dropped by 6.63% to $3.4 million in 2022, then crashed by 43.99% to $1.9 million in 2023, then surged by 40.58% to $2.7 million in 2024, then soared by 3643.65% to $100.5 million in 2025.
Its last three reported values are $100.5 million in Q3 2025, $2.4 million for Q2 2025, and $5.2 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value